Health Care [ 4/12 ] | Pharmaceuticals [ 31/74 ]
NASDAQ | Common Stock
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases.
The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which have completed the Phase III clinical trials for the eradication of Helicobacter pylori infection.
The company has the rights in the United States, Europe, and Canada for P-CAB.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 5, 25 | -1.05 Increased by +24.46% | -1.08 Increased by +2.78% |
| Nov 7, 24 | -1.32 Decreased by -73.68% | -1.49 Increased by +11.41% |
| Aug 8, 24 | -1.56 Decreased by -85.71% | -1.38 Decreased by -13.04% |
| May 9, 24 | -1.42 Decreased by -59.55% | -1.31 Decreased by -8.40% |
| Mar 7, 24 | -1.39 Decreased by -4.51% | -1.08 Decreased by -28.70% |
| Nov 9, 23 | -0.76 Increased by +42.42% | -0.89 Increased by +14.61% |
| Aug 10, 23 | -0.84 Increased by +36.84% | -0.98 Increased by +14.29% |
| May 10, 23 | -0.89 Increased by +16.82% | -1.26 Increased by +29.37% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 29.66 M Increased by +4.25 K% | -74.45 M Increased by +6.43% | Decreased by -250.98% Increased by +97.85% |
| Sep 30, 24 | 16.35 M Increased by +N/A% | -85.58 M Decreased by -97.90% | Decreased by -523.34% Decreased by N/A% |
| Jun 30, 24 | 7.32 M Increased by +N/A% | -91.45 M Decreased by -123.23% | Decreased by -1.25 K% Decreased by N/A% |
| Mar 31, 24 | 1.91 M Increased by +N/A% | -82.85 M Decreased by -119.10% | Decreased by -4.33 K% Decreased by N/A% |
| Dec 31, 23 | 682.00 K Increased by +N/A% | -79.57 M Decreased by -25.40% | Decreased by -11.67 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -43.24 M Increased by +27.51% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -40.97 M Increased by +19.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -37.81 M Increased by +12.92% | Decreased by N/A% Decreased by N/A% |